NASDAQ:PRLD Prelude Therapeutics Q1 2026 Earnings Results & Report $3.32 +0.09 (+2.79%) Closing price 04:00 PM EasternExtended Trading$3.32 0.00 (0.00%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Prelude Therapeutics beat analyst earnings expectations and met on revenue in its Q1 2026 results, released May 12, 2026. The company reported EPS of -$0.13 versus the -$0.27 consensus estimate, while revenue of $4.58 million matched the $4.58 million estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 12, 2026TimeBefore Market OpensConference Call7:00 AM ET Prelude Therapeutics EPS ResultsActual EPS-$0.13Consensus EPS -$0.27Beat/MissBeat by +$0.14One Year Ago EPSN/AEPS Beat Rate8 of last 8 quartersPrelude Therapeutics Revenue ResultsActual Revenue$4.58 millionExpected Revenue$4.58 millionBeat/MissMet ExpectationsYoY Revenue GrowthN/AUpcoming EarningsPrelude Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Prelude Therapeutics Q1 2026 Earnings FAQ Did Prelude Therapeutics beat earnings estimates for Q1 2026? Prelude Therapeutics (NASDAQ:PRLD) reported earnings of -$0.13 per share for Q1 2026, beating the consensus estimate of -$0.27. The report was announced on Tuesday, May 12, 2026. What was Prelude Therapeutics' revenue for Q1 2026? Prelude Therapeutics reported revenue of $4.58 million for Q1 2026, against a consensus estimate of $4.58 million. When is Prelude Therapeutics' next earnings date? Prelude Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Prelude Therapeutics on the company's earnings history page. Prelude Therapeutics Earnings HeadlinesPrelude Therapeutics Incorporated Proceeds With Phase 1 Study Of PRT13722 In Patients With HR+/HER2- Breast CancerOctober 14 at 7:49 PM | marketscreener.comMPrelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in ...October 13 at 8:59 AM | markets.businessinsider.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 15 at 1:00 AM | Altimetry (Ad)Prelude, Lilly Partner On Breast Cancer Combination Trial; Stock UpOctober 13 at 8:59 AM | rttnews.comPrelude Therapeutics, Eli Lilly to Study Breast Cancer Drug Combinations in Phase 1 TrialOctober 13 at 8:59 AM | finance.yahoo.comPrelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast CancerOctober 13 at 7:01 AM | globenewswire.comSee More Prelude Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Prelude Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prelude Therapeutics and other key companies, straight to your email. Email Address About Prelude TherapeuticsPrelude Therapeutics (NASDAQ:PRLD) Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company uses cancer biology, medicinal chemistry and targeted drug-discovery approaches to identify small-molecule therapies designed to address genetic and molecular vulnerabilities in tumors. Prelude’s investigational pipeline has included PRT3789, a selective SMARCA2 protein degrader being developed for cancers with SMARCA4 loss, and PRT2527, a selective cyclin-dependent kinase 9 (CDK9) inhibitor under evaluation for oncology applications. These programs are investigational and are not approved for commercial use. Founded in 2016 and headquartered in Wilmington, Delaware, Prelude conducts research and clinical development activities in the United States. The company was founded by David Mack, Ph.D., who has served as its president and chief executive officer. As a clinical-stage biotechnology company, Prelude’s operations are primarily focused on advancing its drug candidates through clinical testing and establishing potential treatment options for patients with cancer.View Prelude Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
